Navigation Links
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Date:8/29/2010

in New York (NYSE: SNY).

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth o
'/>"/>

SOURCE Sanofi-aventis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
2. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
3. Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients With Very Favorable Genotypes
4. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
5. Study Shows Machine Perfusion Significantly Improves Transplant Results
6. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
7. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
8. Pressure BioSciences, Inc. Reports Record Revenue, Significantly Reduced Operating Loss for the Fourth Quarter of 2008
9. PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
10. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
11. Buehler Motor, Inc., Significantly Expands Customer and Partner Support in North America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... ARIZ. (PRWEB) May 21, 2015 As ... Webb Medical Center (BDWMC), Sun Health Foundation funded a ... center’s new inpatient pharmacy with the most up-to-date features ... open June 2. The pharmacy's 45 staff members will ... larger 4,895-square-foot space in the coming days. , ...
(Date:5/21/2015)... - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: ... on the development of autologous cell therapies, announced ... Society for Cellular Therapy (ISCT) on RepliCel,s autologous ... a Phase 1/2 clinical trial.  The presentation, taking ... PM to 7:00 PM local time, will review ...
(Date:5/21/2015)... May 21, 2015 Tunnell Consulting, ... the firm as senior statistician and Principal, a position ... experience in the management and analysis of complex and ... chemical industries. , “We’re delighted to have Julia join ... data analytics,” said Dr. Philippe Cini, Group Vice President ...
(Date:5/20/2015)... May 20, 2015 Research and Markets ... "Top Technologies in HW_Technical Insights" report to ... report evaluated technology trends in the Health and Wellness ... likely to have an impact in the year 2015. ... the top 10 health and wellness technologies that are ...
Breaking Biology Technology:Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Top Technologies in the Health and Wellness Industry 2015 2
... BioSciences, Inc. (Nasdaq: SGMO ) today announced ... year-end 2008 financial results on Wednesday, February 4, 2009, ... followed by a conference call at 5:00 p.m. ET, ... and webcast. During the conference call, the company will ...
... JMAR Technologies, Inc. (OTCBB: JMAR), a leading innovator ... for the detection of chemical, biological, radiological, nuclear ... microbial contamination detection expert John A. Adams, Ph.D. ... Process Analytical Chemistry (IFPAC) annual meeting on Wednesday, ...
... LOUIS, Jan. 28 ETHEX Corporation, a,subsidiary of ... by KV Pharmaceutical Company on January 26, 2009, ... (all lots within their,expiration dates) at a wholesale ... they may have been manufactured under conditions that ...
Cached Biology Technology:Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast 2Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast 3JMAR Technologies' Chief Scientist Invited by Pfizer Inc. to Speak at IFPAC -- BioSentry Makes Strides in Pharma Market 2JMAR Technologies' Chief Scientist Invited by Pfizer Inc. to Speak at IFPAC -- BioSentry Makes Strides in Pharma Market 3JMAR Technologies' Chief Scientist Invited by Pfizer Inc. to Speak at IFPAC -- BioSentry Makes Strides in Pharma Market 4ETHEX Corporation Issues Nationwide Voluntary Recall of Products 2ETHEX Corporation Issues Nationwide Voluntary Recall of Products 3ETHEX Corporation Issues Nationwide Voluntary Recall of Products 4ETHEX Corporation Issues Nationwide Voluntary Recall of Products 5ETHEX Corporation Issues Nationwide Voluntary Recall of Products 6
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
(Date:5/11/2015)... SAN JOSE, Calif. , May 11, 2015 ... leading developer of human interface solutions, today announced ... Senior Vice President and Chief Financial Officer, reporting ... Mr. Ali replaces Synaptics, current Chief Financial Officer, ... in December 2014. Mr. Ali ...
(Date:5/8/2015)... , May 8, 2015 Synaptics Inc. (NASDAQ: ... today announced that members of the executive management team will ... 43rd Annual Technology, Media and Telecom Conference Date: May ... in Boston, MA Cowen ... 2015 Time: 2:45pm ET Location: The New York Palace Hotel, ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Synaptics to Present at Upcoming Investor Conferences 2
... Molecular biologists, developmental biologists and computer scientists at the ... cracking the code for how gene expression is controlled. ... in January 2006. , A genome milestone was reached ... completed. This has been followed by complete chemical read-outs ...
... cluster of 45 genes coding for antibacterial drug ... cause of hospital-acquired infections worldwide. The study ... , "We expected to find resistance genes," said ... and Genomic Information Laboratory at France's National Center ...
... Thanks to this flexibility--the arm is said to ... freedom"--the octopus is able to generate a vast ... human arm. Nonetheless, despite the huge evolutionary gap ... the octopus arm acts much like a three-jointed ...
Cached Biology News:Cracking the genetic code for control of gene expression 2Supersized 'island' of resistance genes discovered in an infectious bacterium 2How the octopus forms an elbow 2
Fingerprinting II comparative quantification and polymorphism analysis is an optional module that adds comparative quantification and polymorphism analysis functions to the Fingerprinting II Basic so...
... is the most advanced thermal cycler ever ... performance, the Dyad also boasts graphical programming ... navigation via touch pad or mouse. ... economically expanded to a four-bay system with ...
... Tetrad 2 thermal cycler is a completely ... Tetrad chassis, and it accepts the full ... delivers the same precision in thermal performance ... Tetrad thermal cyclers, allowing easy transport of ...
ID clarifier: platform...
Biology Products: